Trump Signs Executive Order to Fast-Track Psychedelic Drug Research and Treatment
President Donald Trump announced significant reforms on Saturday, April 18, 2026, aimed at accelerating access to medical research and treatments based on psychedelic drugs. The president signed an executive order at the White House, directing the federal Food and Drug Administration (FDA) to expedite the review process for drugs such as ibogaine, a substance derived from a central African shrub root that has shown promise in treating post-traumatic stress disorder (PTSD) and substance abuse issues.
Key Reforms and Funding Initiatives
The executive order mandates that the FDA prioritize the evaluation of psychedelic drugs, which are currently largely illegal and can cause hallucinations, for potential reclassification following successful clinical trials. In addition to streamlining regulatory pathways, Trump announced that the United States would dedicate $50 million to federal research specifically focused on ibogaine. This funding aligns with efforts in states like Texas, which has already committed $50 million to studying the drug's therapeutic potential.
During the signing ceremony in the Oval Office, Trump humorously remarked, "Can I have some please?" and added, "I'll take whatever it takes. I don't have time to be depressed." The event was attended by notable figures including US Health Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan, both of whom have been vocal advocates for psychedelic research and reform.
Potential Impacts and Advocacy
Researchers have highlighted ibogaine's potential to address opioid addiction and other substance abuse problems, as well as its efficacy in treating PTSD among military veterans. Trump emphasized the broader implications, stating, "If these turn out to be as good as people are saying, it's going to have a tremendous impact on this country and other countries, too." The reforms are expected to pave the way for increased clinical trials and eventual legal access to these treatments.
Kennedy, who previously criticized the FDA for what he termed its "aggressive suppression of psychedelics," and Rogan, a general supporter of Trump and advocate for responsible psychedelic use, were present to witness the historic signing. Their involvement underscores the growing bipartisan and public interest in exploring alternative medical therapies for mental health and addiction issues.
This executive order marks a pivotal shift in federal drug policy, potentially leading to groundbreaking advancements in mental health care and substance abuse treatment across the nation.
